In this issue of Blood, Richardson et al present convincing results demonstrating that panobinostat, an oral pan-deacetylase inhibitor, in combination with bortezomib and dexamethasone, can recapture responses in bortezomib-refractory multiple myeloma (MM).1 © 2013 by The American Society of Hematology.
Moreau, P. (2013, October 3). Panobinostat to revert bortezomib resistance. Blood. https://doi.org/10.1182/blood-2013-08-522417